These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 1280382)

  • 21. Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.
    McKeating JA; Bennett J; Zolla-Pazner S; Schutten M; Ashelford S; Brown AL; Balfe P
    J Virol; 1993 Sep; 67(9):5216-25. PubMed ID: 7688820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody.
    Ho DD; Fung MS; Cao YZ; Li XL; Sun C; Chang TW; Sun NC
    Proc Natl Acad Sci U S A; 1991 Oct; 88(20):8949-52. PubMed ID: 1717992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
    Sattentau QJ; Moore JP
    J Exp Med; 1995 Jul; 182(1):185-96. PubMed ID: 7540648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding.
    Stamatatos L; Cheng-Mayer C
    J Virol; 1995 Oct; 69(10):6191-8. PubMed ID: 7545244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.
    Moore JP; McKeating JA; Norton WA; Sattentau QJ
    J Virol; 1991 Mar; 65(3):1133-40. PubMed ID: 1995942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.
    Poignard P; Fouts T; Naniche D; Moore JP; Sattentau QJ
    J Exp Med; 1996 Feb; 183(2):473-84. PubMed ID: 8627160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
    Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
    Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins.
    He Y; D'Agostino P; Pinter A
    Vaccine; 2003 Oct; 21(27-30):4421-9. PubMed ID: 14505925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
    Sattentau QJ; Zolla-Pazner S; Poignard P
    Virology; 1995 Jan; 206(1):713-7. PubMed ID: 7530400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
    Callahan LN; Phelan M; Mallinson M; Norcross MA
    J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies.
    Moore JP; McCutchan FE; Poon SW; Mascola J; Liu J; Cao Y; Ho DD
    J Virol; 1994 Dec; 68(12):8350-64. PubMed ID: 7525988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein.
    Shotton C; Arnold C; Sattentau Q; Sodroski J; McKeating JA
    J Virol; 1995 Jan; 69(1):222-30. PubMed ID: 7527084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human immunodeficiency virus type 1 neutralization by a single molecule of V3-targeted antibody.
    Harada S
    Microbiol Immunol; 2002; 46(12):857-62. PubMed ID: 12597360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The C108g epitope in the V2 domain of gp120 functions as a potent neutralization target when introduced into envelope proteins derived from human immunodeficiency virus type 1 primary isolates.
    Pinter A; Honnen WJ; D'Agostino P; Gorny MK; Zolla-Pazner S; Kayman SC
    J Virol; 2005 Jun; 79(11):6909-17. PubMed ID: 15890930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
    Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
    J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure.
    Ditzel HJ; Binley JM; Moore JP; Sodroski J; Sullivan N; Sawyer LS; Hendry RM; Yang WP; Barbas CF; Burton DR
    J Immunol; 1995 Jan; 154(2):893-906. PubMed ID: 7529290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Location, exposure, and conservation of neutralizing and nonneutralizing epitopes on human immunodeficiency virus type 2 SU glycoprotein.
    McKnight A; Shotton C; Cordell J; Jones I; Simmons G; Clapham PR
    J Virol; 1996 Jul; 70(7):4598-606. PubMed ID: 8676486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody.
    Ho DD; McKeating JA; Li XL; Moudgil T; Daar ES; Sun NC; Robinson JE
    J Virol; 1991 Jan; 65(1):489-93. PubMed ID: 1702163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.